Peer Exchange


Advances in Early Treatment Approaches in Multiple Sclerosis

Fred D. Lublin, MD leads a discussion on the 2017 revisions to the McDonald criteria to diagnose multiple sclerosis.

Key opinion leaders discuss red flags in making a multiple sclerosis diagnosis and the possibility for misdiagnosis.

Expert neurologists outline how the use of MRI has changed the diagnosis of multiple sclerosis and the importance of standardized protocols.

Fred D. Lublin, MD, outlines the 4 clinical courses in multiple sclerosis and that they must be framed in time.

The decrease of the modern conversion rate to secondary progressive disease is discussed as well as the importance of a wellness program.

Panelists discuss the importance and value of early identification and treatment of multiple sclerosis.

Key opinion leaders agree there is no consensus on choosing initial therapy for treatment of multiple sclerosis.

Panelists agree there is no treatment algorithm when starting therapy for multiple sclerosis but discuss some factors to consider when choosing therapy.

Implications for using cladribine or diroximel fumarate as therapy for relapsing multiple sclerosis, as well as considerations for selecting an appropriate dose of fingolimod.

Stephen C. Krieger, MD, outlines the ASSESS clinical trial of the orally administered S1P receptor modulator fingolimod.
SAP Partner Banner